Integrated Treatment of Schizophrenia

Psychiatric Services

Volumn 54, Issue 11, 2003, Pages 1499-1507

  Lenroot, Roshel ^a   Bustillo, Juan R ^a   Lauriello, John ^a   Keith, Samuel J ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYCLOSERINE; FLUPHENAZINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; CLINICAL TRIAL; COGNITION; DISEASE SEVERITY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERSALIVATION; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; LONG QT SYNDROME; LOW DRUG DOSE; META ANALYSIS; NAUSEA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL PSYCHOLOGY; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN;

CLINICAL TRIALS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FAMILY THERAPY; HUMANS; PATIENT CARE TEAM; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-HELP GROUPS; SOCIALIZATION; TREATMENT OUTCOME;

EID: 0242362749     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.11.1499     Document Type: Review

References (68)

1. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. rev. Washington, DC, American Psychiatric Association, 2000
2. Rice DP: The economic impact of schizophrenia. Journal of Clinical Psychiatry 60: 4-6, 28-30, 1999
3. Mental Health: A Report of the Surgeon General. Rockville, Md, US Department of Health and Human Services, 1999
4. Buchanan RW, Carpenter WT: Schizophrenia: introduction and overview, in Comprehensive Textbook of Psychiatry, vol 1. Edited by Sadock BJ, Sadock VA. Philadelphia, Lippincott Williams & Wilkins, 2000
5. Hogarty GE, Ulrich RF: The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Journal of Psychiatric Research 32:243-250, 1998
6. Liberman RP: Psychosocial treatments for schizophrenia. Psychiatry 57:104-114, 1994
7. Brown GW, Birley JL, Wing JK: Influence of family life on the course or schizophrenic disorders: a replication. British Journal of Psychiatry 121:241-258, 1972
8. Jablensky A, Sartorius N, Ernberg C, et al: Schizophrenia: manifestations, incidence, and course in different cultures: a World Health Organization ten-country study. Psychological Medicine Monograph Supplement 20:1-97, 1992
9. Bustillo JR, Lauriello J, Keith SJ: Schizophrenia: improving outcome. Harvard Review of Psychiatry 6:229-240, 1999
10. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 154:1-63, 1997
11. Herz MI, Marder SR: Schizophrenia: Comprehensive Treatment and Management. Philadelphia, Lippincott Williams & Wilkins, 2002
12. Hafner H, an der Heiden W: Course and outcome of schizophrenia, in Schizophrenia. Edited by Hirsch SR, Weinberger D. Malden, Mass, Blackwell, 2003
13. May PRA: Treatment or Schizophrenia: A Comparative Study of Five Treatment Models. New York, Science House, 1968
14. Hogarty GE, Goldberg SC, Schooler NR: Drug and sociotherapy in the aftercare of schizophrenic patients: III. adjustment of nonrelapsed patients. Archives of General Psychiatry 31:609-618, 1974
15. Hogarty GE, Schooler NR, Ulrich R, et al: Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36:1283-1294, 1979
16. Brown GW, Rutter M: The measurement of family activities and relationships: a methodological study. Human Relations Supplement 2:10-15, 1966
17. Goldstein MJ, Rodnick EH, Evans JR, et al: Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry 35:1169-1177, 1978
18. Hogarty GE, McEvoy JP, Munetz M, et al: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. Archives of General Psychiatry 45:797-805, 1988
19. Marder SR, Wirshing WC, Mintz J, et al: Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. American Journal of Psychiatry 153:1585-1592, 1996
20. Marder SR: Integrating pharmacological and psychosocial treatments for schizophrenia. Acta Psychiatrica Scandinavica Supplement 102:87-90, 2000
21. Schooler NR, Keith SJ, Severe JB, et al: Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Archives of General Psychiatry 54:453-463, 1997
22. Mueser KT, Sengupta A, Schooler NR, et al: Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden. Journal of Consulting and Clinical Psychology 69:3-12, 2001
23. Rosenheck R, Tekell J, Peters J, et al: Does participation in psychosocial treatment augment the benefit of clozapine? Archives of General Psychiatry 55:618-625, 1998
24. Liberman RP, Gutkind D, Mintz J, et al: Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Comprehensive Psychiatry 43:469-473, 2002
25. Lehman AF: Developing an outcomes-oriented approach for the treatment of schizophrenia. Journal of Clinical Psychiatry 60(suppl 19):30-35, 1999
26. Attkisson C, Cook J, Karno M, et al: Clinical services research. Schizophrenia Bulletin 18:561-626, 1992
27. Mead S, Copeland ME: What recovery means to us: consumer' perspectives. Community Mental Health Journal 36: 315-331, 2000
28. Corrigan PW, Liberman RP, Engel JD: From noncompliance to collaboration in the treatmenf of schizophrenia. Hospital and Community Psychiatry 41:1203-1211, 1990
29. Spohn HE, Strauss ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology 98:367-380, 1989
30. Purdon SE, Jones BDW, Stip E, et al: Neurosychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Archives of General Psychiatry 57:249-258, 2000
31. Velligan DI, Miller AL: Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Journal of Clinical Psychiatry 60:25-28, 1999
32. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 158:1367-1377, 2001
33. Goff DC, Tsai G, Manoach DS, et al: Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry 152:1213-1215, 1995
34. Goff DC, Tsai G, Levitt J, et al: A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 56:21-27, 1999
35. Geddes J, Freemantle N, Harrison P, et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321:1371-1376, 2000
36. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553-564, 2003
37. Lehman AF, Steinwachs DM: At issue: translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 24:1-10, 1998
38. Miyamoto S, Stroup TS, Duncan GE, et al: Acute pharmacological treatment of schizophrenia, in Schizophrenia. Edited by Hirsch SR, Weinberger D. Malden, Mass, Blackwell, 2003
39. Lindstrom E, Bingefors K: Patient compliance with drug therapy in schizophrenia: economic and clinical issues. Pharmacoeconomics 18:106-124, 2000
40. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophrenia Bulletin 21: 419-429, 1995
41. Velligan DI, Lam F, Ereshefsky L, et al: Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatric Services 54:665-667, 2003
42. Mueser KT, Glynn SM: Family intervention for schizophrenia, in Best Practice: Developing and Promoting Empirically Supported Interventions. Edited by Dobson KS, Craig KD. Newbury Park, Calif, Sage, 1998
43. Tarrier N, Barrowclough C, Porceddu K, et al: The Salford Family Intervention Project: relapse rates of schizophrenia at five and eight years. British Journal of Psychiatry 165:829-832, 1994
44. Pharoah FM, Mari JJ, Streiner D: Family intervention for schizophrenia. Cochrane Review, update software. New York, Oxford University Press, 2003
45. Pilling S, Bebbington P, Kuipers E, et al: Psychological treatments in schizophrenia: 1. meta-analysis of family intervention and cognitive behavioral therapy. Psychological Medicine 32:763-782, 2002
46. Hogarty GE, Kornblith SJ, Greenwald D, et al: Personal therapy: a disorder-relevant psychotherapy for schizophrenia. Schizophrenia Bulletin 21:379-393, 1995
47. Tarrier N, Beckett R, Harwood S, et al: A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. outcome. British Journal of Psychiatry 162:524-532, 1993
48. Kuipers E, Garety P, Fowler D, et al: London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis: I. effects of the treatment phase. British Journal of Psychiatry 171:319-327, 1997
49. Drury V, Birchwood M, Cochrane R, et al: Cognitive therapy and recovery from acute psychosis: a controlled trial. I. impact on psychotic symptoms. British Journal of Psychiatry 169:593-601, 1996
50. Kemp R, Kirov G, Everitt B, et al: Randomised controlled trial of compliance therapy: 18-mouth follow-up. British Journal of Psychiatry 172:413-419, 1998
51. Bellack AS, Mueser KT. Psychosocial treatment for schizophrenia. Schizophrenia Bulletin 19:317-336, 1993
52. Braff DL: Information processing and attention dysfunctions in schizophrenia. Schizophrenia Bulletin 19:233-259, 1993
53. Brenner HD, Hodel B, Roder V, et al: Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia. Schizophrenia Bulletin 18:21-26, 1992
54. Drake RE, Becker DR, Biesanz JC, et al: Rehabilitative day treatment vs supported employment: I. vocational outcomes. Community Mental Health Journal 30:519-532, 1994
55. Bond GR, Drake RE, Mueser KT, et al: An update on supported employment for people with severe mental illness. Psychiatric Services 48:335-346, 1997
56. Mueser KT, Bond GR, Drake RE, et al: Models of community care for severe mental illness: a review of research on case management. Schizophrenia Bulletin 24: 37-74, 1998
57. Lehman AF, Dixon LB, Kernan E, et al: A randomized trial of assertive community treatment for homeless persons with severe mental illness. Archives of General Psychiatry 54:1038-1043, 1997
58. Burns BJ, Santos AB: Assertive community treatment: an update of randomized trials. Psychiatric Services 46:669-675, 1995
59. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23:637-651, 1997
60. Haynes RB, McDonald H, Garg AX, et al: Interventions for helping patients to follow prescriptions for medications, in The Cochrane Library, Issue 2. New York, Oxford University Press, 2003
61. Garety PA, Fowler D, Kuipers E: Cognitive-behavioral therapy for medication-resistant symptoms. Schizophrenia Bulletin 26:73-86, 2000
62. Sensky T, Turkington D, Kingdom D, et al: A randomized controlled trial of cognitive-behavioral therapy for persistant symptoms of schizophrenia resistant to medication. Archives of General Psychiatry 57:165-172, 2000
63. Regier DA, Boyd JH, Burke JD, et al: One-month prevalence of mental disorders in the United States based on 5 epidemiologic catchment-area sites. Archives of General Psychiatry 48:977-986, 1988
64. Drake RE, Mueser KT: Psychosocial approaches to dual diagnosis. Schizophrenia Bulletin 26:105-118, 2000
65. Bridging Science and Service. Bethesda, Md, National Institute of Mental Health, 1999
66. Drhke RE, Goldman HH, Leff HS: Implementing evidence-based practices in routine mental health service settings. Psychiaatric Services 52:179-182, 2001
67. Schoenwald SK, Hoagwood K: Effectiveness, transportability, and dissemination of interventions: what matters when? Psychiatric Services 52:1190-1197, 2001
68. Newman FL, Tejeda MJ: The need for research that is designed to support decisions in the delivery of mental health services. American Psychologist 51:1040-1049, 1996